MedicaidPrior AuthHigh impact
KMAP BULLETIN: Preferred Drug List Update
Kansas Medicaid (KanCare)·KS · Rheumatology, Gastroenterology, Hematology +2 more·Pharmacy
Effective date
Sep 30, 2024
We identified it
Jun 21, 2026
Summary
Kansas Medicaid (KMAP) is moving several high-cost specialty medications to non-preferred status requiring prior authorization, while making tofacitinib (Xeljanz) products preferred. This affects rheumatology, gastroenterology, and other specialty drug prescriptions.
Action Required
Immediately: Update prior authorization workflow for non-preferred medications including adalimumab, infliximab, tocilizumab, and upadacitinib products. Train staff to verify PDL status before prescribing specialty medications. Add PDL prior authorization requirements to EMR alerts for Kansas Medicaid patients. Monitor MCO implementation dates as they may vary from state policy date.